List of Excipients in Branded Drug TRANEXAMIC ACID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AvPAK	TRANEXAMIC ACID	tranexamic acid	50268-772	CELLULOSE, MICROCRYSTALLINE
AvPAK	TRANEXAMIC ACID	tranexamic acid	50268-772	HYPROMELLOSE
AvPAK	TRANEXAMIC ACID	tranexamic acid	50268-772	MAGNESIUM STEARATE

Generic Drugs Containing TRANEXAMIC ACID

Company	Ingredient	NDC	Excipient
American Regent Inc	tranexamic acid	0517-0960	WATER
Actavis Pharma Inc	tranexamic acid	0591-3720	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	tranexamic acid	0591-3720	COPOVIDONE K25-31

What are the Most Frequently-Used Excipients in TRANEXAMIC ACID?

# Of NDCs	Excipient
10	CELLULOSE, MICROCRYSTALLINE
3	COPOVIDONE K25-31
4	CROSCARMELLOSE SODIUM

Tranexamic Acid Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Tranexamic acid is an established, low-cost antifibrinolytic with broad demand in menstrual bleeding, surgery, trauma, postpartum hemorrhage, dentistry, dermatology and topical cosmetic products. Its active ingredient is off-patent, so commercial differentiation depends on formulation performance, administration route, excipient tolerability, regulatory positioning, supply reliability and distribution rather than exclusivity over tranexamic acid itself.

The strongest opportunities are patient-friendly oral products, ready-to-use topical formulations, low-volume injectable presentations, pediatric or dysphagia-friendly dosage forms, and combination products that improve adherence without introducing avoidable excipient or regulatory risk.

What is tranexamic acid and where is it used?

Tranexamic acid is a synthetic lysine analogue that inhibits plasminogen activation and reduces fibrin degradation. FDA-approved uses include short-term treatment of cyclic heavy menstrual bleeding and reduction of bleeding during dental extraction in patients with hemophilia. Injectable tranexamic acid is used in several surgical and trauma settings, although indications vary by jurisdiction and product label.[1][2]

Attribute	Tranexamic acid
Drug class	Antifibrinolytic
Primary mechanism	Blocks lysine-binding sites on plasminogen
Common oral strength	650 mg tablets in the U.S. Lysteda product
Common injectable strength	100 mg/mL
Key approved U.S. products	Lysteda tablets; Cyklokapron injection
Main commercial markets	Heavy menstrual bleeding, surgery, trauma, postpartum hemorrhage, dental care
Generic status	Mature generic market
Biosimilar relevance	None; tranexamic acid is a small molecule
Core commercial constraint	Price competition and limited product exclusivity

The molecule is highly water-soluble, which simplifies aqueous injectable development but creates formulation challenges for taste, tablet size, moisture control and topical sensory properties.

What excipients are used in tranexamic acid formulations?

Excipients vary by manufacturer, dosage form and jurisdiction. U.S. Lysteda tablets use conventional pharmaceutical excipients for compression, disintegration, lubrication and film coating. Cyklokapron injection relies primarily on water for injection and pH adjustment.[1][3]

Oral tablets

Typical excipient functions include:

Function	Common excipient classes	Commercial purpose
Diluent	Microcrystalline cellulose, lactose, starch derivatives	Controls tablet size and compressibility
Binder	Povidone, pregelatinized starch	Improves mechanical strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, stearic acid	Reduces manufacturing friction
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, talc	Controls appearance, swallowability and protection
Taste-management aid	Film coating, sweeteners or flavor systems	Reduces bitterness in chewable or orally disintegrating products

The principal formulation issue is dose burden. A 650 mg tablet contains a relatively large active load, and regimens for heavy menstrual bleeding may require two tablets taken three times daily for up to five days.[1] Excipient selection should therefore prioritize high drug loading, low tablet mass and reliable disintegration.

Injectable products

Injectable tranexamic acid is commonly formulated as a sterile aqueous solution. The excipient strategy is comparatively simple:

• Water for injection as the vehicle.
• Hydrochloric acid or sodium hydroxide for pH adjustment.
• Container-closure materials compatible with an aqueous, high-concentration solution.
• Low-particulate, low-endotoxin manufacturing controls.

Commercial value comes less from novel excipients than from ready-to-administer packaging, dose accuracy, compatibility, stability, sterility assurance and hospital workflow.

Topical products

Topical tranexamic acid products are sold or developed for melasma, post-inflammatory hyperpigmentation, redness and cosmetic brightening. These products may use:

• Water-based gels.
• Emulsions and creams.
• Serums.
• Liposomal or vesicular systems.
• Hydrogel patches.
• Mucoadhesive oral gels or rinses.

Topical development requires control of pH, preservation, oxidation, microbial robustness, skin feel and delivery into the intended skin layers. A formulation that improves local retention while limiting systemic exposure may support a stronger commercial position than a simple aqueous serum.

What excipient strategy best supports tranexamic acid commercial products?

The optimal strategy depends on route and claim scope.

Strategy for oral tablets

A generic immediate-release tablet should use a well-understood excipient system with broad regulatory precedent. The formulation target is:

1. High active loading.
2. Rapid and reproducible disintegration.
3. Low friability.
4. Acceptable swallowability.
5. Minimal sensitivity to humidity.
6. Bioequivalence to the reference product.

A direct-compression platform using microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide and magnesium stearate can reduce process complexity. Wet granulation may improve content uniformity and tablet robustness but adds drying and moisture-control requirements.

For a premium product, the strongest opportunities are not conventional tablets. They include:

• Smaller high-load tablets.
• Orally disintegrating tablets.
• Chewable tablets with effective bitterness masking.
• Sachets or powders for reconstitution.
• Oral liquids for patients with dysphagia.
• Calendar blister packs aligned with menstrual-cycle dosing.

Taste masking is important because tranexamic acid has a noticeable bitter or saline taste. Polymer coating, ion-exchange resins, multiparticulate encapsulation and carefully selected sweetener-flavor systems can support pediatric or dysphagia products. The excipient system must not materially delay release or create a clinically meaningful food effect.

Strategy for injectable products

The commercial focus should be operational rather than chemically novel. Hospitals value:

• Ready-to-use prefilled syringes.
• Single-dose vials.
• Small-volume presentations.
• Clear labeling for route and concentration.
• Compatibility with emergency carts.
• Reduced preparation steps.
• Extended stability under controlled temperature conditions.

A prefilled syringe can command a premium if it reduces medication-preparation errors and nursing time. The product must address extractables, leachables, syringe material compatibility, particulate control and container-closure integrity.

Strategy for topical products

Topical products have the largest formulation space but also the greatest regulatory ambiguity. A cosmetic product may have a faster route to market in some jurisdictions, but claims must remain within cosmetic boundaries. Claims to treat melasma, hyperpigmentation caused by disease or other medical conditions can trigger drug regulation.

Promising excipient platforms include:

Platform	Potential benefit	Main development issue
Hydrogel	Cooling feel and easy application	Water activity and preservative control
Oil-in-water cream	Consumer familiarity and barrier support	Stability and active partitioning
Liposomal system	Possible local delivery enhancement	Scale-up and characterization
Mucoadhesive gel	Longer residence time in oral cavity	Taste and mucosal tolerability
Anhydrous serum	Reduced microbial risk	Solubility and skin feel
Spray or foam	Convenient application	Dose uniformity and packaging compatibility

A topical product should be evaluated for tranexamic acid deposition, permeation, irritation, sensitization and systemic exposure. Claims of superior delivery require comparative data rather than reliance on the presence of a carrier such as liposomes.

What patents protect tranexamic acid products?

Tranexamic acid has no meaningful active-ingredient composition-of-matter barrier in the commercial markets reviewed through established FDA product information. The U.S. products Lysteda and Cyklokapron are approved products with generic competition, and the principal opportunity is therefore formulation, device, manufacturing or brand differentiation rather than a new-molecule patent position.[1][3][4]

Formulation patents

Potential formulation patent themes include:

• Modified-release oral delivery.
• Taste-masked oral dosage forms.
• Orally disintegrating tablets.
• Stable topical emulsions.
• Liposomal or nanoparticle delivery.
• Mucoadhesive systems.
• Ready-to-use injectable presentations.
• Combination products containing tranexamic acid and another active.

A formulation patent must establish a defensible technical relationship between the excipient system and a measurable performance advantage. Broad claims covering tranexamic acid with routine excipients are vulnerable to obviousness and enablement challenges.

Method-of-use patents

Method-of-use claims may address:

• Specific bleeding indications.
• Dosing schedules.
• Patient subgroups.
• Topical treatment of dermatologic conditions.
• Perioperative administration protocols.
• Combination therapy.

Method claims face enforcement and prescribing-use complications where generic products carry broad labels or where the proposed use is already supported by clinical literature. Commercial value is higher when the method is linked to a differentiated dosage form, device or restricted label.

Manufacturing and process patents

Process claims may protect:

• Crystallization and polymorph control.
• High-purity active production.
• Removal of process impurities.
• Sterile filling.
• Improved stability.
• Continuous manufacturing.
• Low-cost high-yield production.

For an established active, process economics can be more important than patent duration. A supplier with reliable GMP production, multiple qualified sites and low impurity burden may capture share even without a strong downstream formulation patent.

What is the FDA regulatory status of tranexamic acid?

FDA-approved tranexamic acid products include oral tablets for cyclic heavy menstrual bleeding and intravenous injection for specific bleeding-related uses.[1][3] Generic products may be approved under abbreviated new drug applications when they demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product.

The regulatory pathway depends on the claim:

Product	Likely U.S. pathway	Key requirements
Standard oral tablet	ANDA	Pharmaceutical equivalence and bioequivalence
Modified-release tablet	ANDA or 505(b)(2), depending on reference and design	Comparative release and clinical bridging
New topical drug	505(b)(2) or NDA	CMC, safety and efficacy support
Cosmetic topical	Cosmetic framework if claims remain cosmetic	Ingredient safety and labeling compliance
New injectable presentation	ANDA or 505(b)(2)	Sterility, container compatibility and comparative performance
Combination product	NDA or 505(b)(2)	Combination rationale and product-specific evidence

Excipients used in approved oral and injectable products reduce regulatory risk. Novel excipients may improve differentiation but increase the burden of safety justification, impurity control and global acceptability.

When does tranexamic acid lose exclusivity?

Tranexamic acid has already lost small-molecule market exclusivity in the United States. There is no biosimilar pathway because the drug is not a biologic. Generic competition is therefore the primary source of pricing pressure.

The commercial exclusivity analysis should distinguish among:

• Active-ingredient exclusivity, which is exhausted.
• Product-specific patents, which may cover a formulation or use.
• Regulatory exclusivity, which may apply to a new indication or pediatric program.
• Trade-secret manufacturing advantages.
• Trademark and brand recognition.
• Supply contracts and hospital formulary access.

For Lysteda, the commercial moat is narrower than for a recently launched branded drug. For Cyklokapron injection, hospital purchasing, shortage management, supplier qualification and presentation convenience may matter more than patent rights.

Which companies are competing in tranexamic acid?

Competition exists across active pharmaceutical ingredient supply, generic finished dosage forms, hospital injectables and consumer-facing topical products.

Competitive segments

Segment	Competitive basis
Oral generics	Price, bioequivalence, supply reliability
Hospital injection	Sterile capacity, availability, packaging and contracts
API supply	GMP quality, cost, impurity profile and geographic redundancy
Dermatology products	Texture, tolerability, delivery claims and brand
Consumer products	Packaging, cosmetic positioning and distribution
Specialty formulations	Patent position, clinical evidence and adherence benefit

The most defensible commercial products will solve a practical problem. A smaller tablet, ready-to-use syringe, stable topical formulation or well-supported indication has greater value than an undifferentiated tranexamic acid product with a new excipient label.

What Paragraph IV and litigation risks affect tranexamic acid?

Paragraph IV risk is most relevant when a company challenges a listed patent for a branded tranexamic acid product or seeks approval for a product that may fall within a formulation or method claim. For mature generic products, litigation risk typically centers on:

• Whether a listed claim is valid.
• Whether the generic product infringes.
• Whether the claim is properly listed in the Orange Book.
• Whether a carve-out removes the accused method of use.
• Whether a formulation difference affects bioequivalence.
• Whether a settlement delays generic launch.

Standard oral tranexamic acid products face limited molecule-level litigation exposure because the active ingredient is long established. Risk increases for modified-release, topical, device-linked and combination products.

No broad biosimilar litigation framework applies. Any dispute would be handled under small-molecule patent and regulatory rules rather than the Biologics Price Competition and Innovation Act.

What Orange Book status applies to tranexamic acid?

The Orange Book identifies FDA-approved drug products, therapeutic equivalence information and, where applicable, listed patents and exclusivity. Tranexamic acid products should be reviewed by product number rather than by active ingredient alone because oral tablets, injection products and formulations may have separate listings.[4]

For diligence, the relevant questions are:

1. Is the product listed as a reference listed drug?
2. Are patents listed for the specific NDA?
3. Has any patent term extension or pediatric exclusivity applied?
4. Are method-of-use patents subject to a section viii carve-out?
5. Does the proposed generic formulation match the reference product sufficiently for ANDA approval?

A current Orange Book review is essential before filing a Paragraph IV certification or finalizing a launch date.

How strong is the tranexamic acid patent estate?

The patent estate is weak at the active-ingredient level and potentially moderate at the formulation level.

Patent layer	Relative strength
Tranexamic acid composition of matter	Very weak or exhausted
Conventional immediate-release tablet	Weak
New excipient combination with demonstrated performance	Moderate
Modified-release delivery	Moderate if clinically differentiated
Topical delivery system	Moderate, dependent on claim breadth
Ready-to-use injectable device	Moderate
Manufacturing process	Moderate to strong if difficult to design around
New method of use	Variable and indication-dependent

Patent value depends on claim scope, freedom to operate, experimental support and the ability to detect infringement. A narrow formulation patent may protect a premium product but have little effect on low-cost generic tablets.

What geographic opportunities exist for tranexamic acid?

Tranexamic acid has global demand because bleeding-related indications occur across hospital, surgical and primary-care settings. Opportunity is strongest where access, supply continuity and administration simplicity are limited.

Priority markets

• United States: mature generics, hospital contracting and specialty formulation opportunities.
• European Union: broad use in surgery and bleeding management, with country-specific reimbursement.
• Japan: established use and high expectations for quality and presentation.
• India: large generic and API manufacturing base.
• Latin America: demand for affordable oral and injectable products.
• Southeast Asia: hospital injectable and obstetric applications.
• Africa: opportunity for stable, low-cost products and reliable supply.

Geographic expansion requires country-specific review of approved indications, excipient acceptability, labeling, pharmacopoeial standards, import controls and local manufacturing requirements.

What generic launch scenarios exist?

Scenario 1: Low-cost immediate-release tablet

This is the fastest path but has the lowest margin. Success depends on manufacturing cost, supply reliability, pharmacy contracting and a clean bioequivalence package.

Scenario 2: Smaller or patient-friendly oral product

A high-load tablet, orally disintegrating tablet or taste-masked product can target adherence and dysphagia. The product may support a 505(b)(2) strategy if it departs materially from the approved reference product.

Scenario 3: Ready-to-use injectable

A prefilled syringe or standardized small-volume vial can generate hospital value by reducing preparation time and dosing errors. Device and container-closure development become central to the product plan.

Scenario 4: Dermatology formulation

A topical product can access a larger consumer market, but claim wording determines whether the product remains cosmetic or enters drug regulation. Clinical evidence and skin tolerability are key differentiators.

Scenario 5: Specialty combination product

Combination products may address postoperative bleeding, dental care or dermatologic use. The main barriers are clinical rationale, interaction assessment, regulatory classification and enforceable intellectual property.

Key Takeaways

• Tranexamic acid is a mature, off-patent small molecule with no biosimilar risk.
• Excipient selection is commercially important because the active ingredient provides little exclusivity.
• Oral products should prioritize high drug loading, rapid disintegration, swallowability and taste masking.
• Injectable products should focus on ready-to-use packaging, sterility, stability and hospital workflow.
• Topical products offer the widest formulation opportunity but face claim-classification and clinical-evidence risks.
• Formulation, device, manufacturing and method-of-use patents are more relevant than composition-of-matter patents.
• Generic tablets face strong price competition; differentiated delivery systems can support higher margins.
• Current Orange Book and patent-docket review is required before a Paragraph IV filing or launch-date forecast.
• The most attractive opportunities combine a practical administration benefit with a defensible regulatory and intellectual-property position.

FAQs About Tranexamic Acid Excipient and Commercial Strategy

Can tranexamic acid be formulated as an orally disintegrating tablet?

Yes. The main technical barriers are the high active load, bitterness, tablet friability and achieving rapid disintegration without excessive tablet mass. Taste masking and particle engineering may be more valuable than simply adding sweeteners.

Which excipients are most suitable for a tranexamic acid oral liquid?

A suitable system may include purified water, a buffering agent, sweetener, flavor, viscosity modifier and antimicrobial preservative where justified. The formulation must control taste, microbial growth, chemical stability and dose uniformity.

Is a liposomal tranexamic acid product automatically patentable?

No. Liposomal delivery alone is unlikely to provide a strong patent position. Patentability depends on specific composition, particle characteristics, manufacturing method and demonstrated technical performance.

Can a tranexamic acid cosmetic product make hyperpigmentation-treatment claims?

The answer depends on jurisdiction and claim wording. Cosmetic brightening claims may remain outside drug regulation, while claims to treat a disease or medical condition can trigger drug classification and require a drug approval pathway.

What is the highest-value commercial opportunity for tranexamic acid?

In mature markets, a ready-to-use injectable or patient-friendly oral formulation is more likely to create defensible value than another conventional tablet. In consumer dermatology, a stable, well-tolerated topical product with credible comparative evidence has the strongest differentiation potential.

References

1. U.S. Food and Drug Administration. (2023). Lysteda (tranexamic acid) tablets: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Tranexamic acid injection: Prescribing information. FDA.

3. Pfizer Laboratories. (2022). Cyklokapron (tranexamic acid) injection: Prescribing information. Pfizer.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. World Health Organization. (2017). WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage. World Health Organization.

6. CRASH-2 Trial Collaborators. (2010). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage. The Lancet, 376(9734), 23-32.

7. WOMAN Trial Collaborators. (2017). Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with postpartum haemorrhage. The Lancet, 389(10084), 2105-2116.